Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Research output: Contribution to journal › Article
Prediction of radiographic progression (RP) in early rheumatoid arthritis (eRA) would be very useful for optimal choice among available therapies. We evaluated a multi-biomarker disease activity (MBDA) score, based on 12 serum biomarkers as a baseline predictor for 1-year RP in eRA.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Annals of the Rheumatic Diseases|
|Publication status||Published - 2015|